| B/NL/11/002 | Netherlands | 10/05/2012 | University Medical Center Groningen | | |
| B/NL/10/004 | Netherlands | 30/04/2012 | Intervet International bv | Non-pathogenic Mannheimia haemolytica and Pasteurella multocida | |
| B/IS/12/01 | Iceland | 17/04/2012 | BN ImmunoTherapeutics, Inc. | Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” | |
| B/ES/12/09 | Spain | 17/02/2012 | IrsiCaixa AIDS Research Institute | Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART) | |
| B/ES/12/10 | Spain | 17/02/2012 | IrsiCaixa AIDS Research Institute | Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART) | |
| B/ES/12/11 | Spain | 17/02/2012 | Transgene S.A. | The project, JX594-HEP018 clinical trial, is entitled “A Phase 2b Randomized, Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment (JX594-HEP018)”. | |
| B/ES/12/14 | Spain | 17/02/2012 | BN ImmunoTherapeutics, Inc. | Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer | |
| B/ES/12/17 | Spain | 17/02/2012 | FUNDACION PARA LA INVESTIGACION
BIOMEDICA HOSPITAL UNIVERSITARIO INFANTIL NIÑO JESUS | “Phase I open Phase I trials to assess efficacy and safety of treatment with autologous mesenchymal cells infected with an oncolitic adenovirus (CELYVIR) in the treatment of paediatric patients with refractory or relapsed solid tumors” | |
| B/EE/12/01 | Estonia | 17/02/2012 | BN ImmunoTherapeutics, Inc. | Clinical Study BNIT-PRV-301, "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer" | |
| B/BE/11/V3 | Belgium | 08/02/2012 | Laboratorios Hipra, S.A. | Assessment of the safety and efficacy of the live vaccine PB-116 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae | |
| B/CZ/12/01 | Czech Republic | 08/02/2012 | BN ImmunoTherapeutics, Inc. | Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer | |
| B/DE/10/213 | Germany | 16/01/2012 | Intervet International bv | A non-pathogenic Rhodococcus equi strain as vaccine in horses | |
| B/GB/11/R44/01 | United Kingdom | 25/10/2011 | BN ImmunoTherapeutics, Inc. | Clinical Study BNIT-PRV-301, "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer" | |
| B/GB/11/R44/01/W | United Kingdom | 25/10/2011 | BN ImmunoTherapeutics, Inc. | Clinical Study BNIT-PRV-301, ""A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer" | |
| B/BE/11/BVW1 | Belgium | 17/10/2011 | Transgene S.A. | A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC) | |
| B/DE/08/PEI706 | Germany | 05/10/2011 | MedImmune, LLC | Clinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants”. | |
| B/HU/11/01 | Hungary | 27/09/2011 | Transgene S.A. | The project, TG4010.14 clinical trial, is entitled “A Phase IIb/III randomized, double blind, placebo controlled, study comparing first line therapy with or without the therapeutic vaccine TG4010 in patients with stage IV non small cell lung cancer (NSCLC)”. | |
| B/DE/09/PEI984 | Germany | 30/08/2011 | Mologen AG | A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination with a DNA-based Double Stem Loop Immunomodulator in Patients with Advanced Renal Cell Carcinoma (ASET Study) | |
| B/DE/10/PEI1035 | Germany | 30/08/2011 | Transgene S.A. | A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C | |
| B/DE/10/PEI1173 | Germany | 30/08/2011 | Genelux GmbH | Phase I/II study of intraperitoneal administration of GL-ONC1, a genetically modified vaccinia virus, in patients with peritoneal carcinomatosis | |
| B/DE/05/PEI35 | Germany | 30/08/2011 | Hesperion Ltd | A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of BIOBYPASS® (AdGVVEGF121.10NH) delivered by NOGA™-guided/MYOSTAR™ catheter in “no option” patients with Class II-IV stable angina | |
| B/DE/06/PEI210 | Germany | 30/08/2011 | Bavarian Nordic GmbH | HIV-POL-001: Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of two different doses of recombinant MVA-HIV polytope vaccine (MVA-mBN32) in HIV negative 18-50 year old Healthy Volunteers | |
| B/DE/06/PEI231 | Germany | 30/08/2011 | Transgene S.A. | A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer. | |
| B/DE/08/PEI574 | Germany | 30/08/2011 | Vakzine Projekt Management GmbH | Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison with BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination | |
| B/NL/11/001 | Netherlands | 24/08/2011 | Netherlands Cancer Institute | Ex vivo retroviral transduction of human T lymphocytes with melanoma-specific T cell receptor genes | |
| B/NL/11/003 | Netherlands | 24/08/2011 | Leiden University Medical Center | Administration of donor specific T-cells transduced ex vivo using a retroviral vector coding for a leukemia-specific TCR, as a cellular treatment after allogeneic stem cell transplantation for patients with refractory or relapsed hematological malignancies. | |
| B/IE/11/451-A | Ireland | 09/08/2011 | Royal College of Surgeons In Ireland | Phase 1 clinical trial to assess the safety and immunogenicity of malaria vaccine | |
| B/IE/11/451-B | Ireland | 09/08/2011 | Royal College of Surgeons In Ireland | Phase 1 clinical trial to assess the safety and immunogenicity of malaria vaccine | |
| B/ES/11/28 | Spain | 05/07/2011 | Transgene S.A. | A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). | |
| B/ES/11/27 | Spain | 22/06/2011 | FUNDACION PARA LA INVESTIGACION
BIOMEDICA HOSPITAL UNIVERSITARIO INFANTIL NIÑO JESUS | Phase I clinical trial to evaluate ICOVIR5 treatment of paediatric refractory or recurrent tumors of the Central Nervous System | |
| B/ES/11/25 | Spain | 17/05/2011 | Clínica Universidad de Navarra | Phase I-II therapeutic vaccination clinical trial in patients with chronic hepatitis C by administration of autologous dendritic cells transduced with an adenoviral vector encoding NS3 protein | |
| B/SE/10/EU-2010-023103-94 | Sweden | 29/04/2011 | Uppsala University | Phase I/IIa AdCD40L immunogene therapy for malignant melanoma in patients with disseminated disease | |
| B/GB/10/R40/01 | United Kingdom | 23/12/2010 | Emergent Product Development UK Ltd | Understanding typhoid disease after vaccination: A single centre, randomized, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy volunteer challenge model with the licensed Ty21a vaccine as a positive control | |
| B/NL/10/002 | Netherlands | 24/11/2010 | Utrecht University | Vaccination with naked DNA, encoding the xenogenetic human tyrosinase for the induction of specific defence against melanoma cells in dog | |
| B/NL/09/004 | Netherlands | 22/10/2010 | Intervet International bv | A non-pathogenic Rhodococcus equi strain as vaccine in horses. | |
| B/RO/10/08 | Romania | 28/07/2010 | Parexel International Romania SRL | A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C. | |
| B/IT/10/01 | Italy | 17/06/2010 | Istituto Zooprofilatico Sperimentale Umbria Marche | Improve tools and strategies for the prevention and the control of classical swine fever | |
| B/IE/10/362 | Ireland | 21/05/2010 | TMC Pharma Services Ltd | A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency | |
| B/NL/10/003 | Netherlands | 11/05/2010 | Leiden University Medical Center | Intradermal vaccination with naked DNA encoding the fusion protein domain1 of tetanus toxin fragment C and MART-1(aa 26-35) for the induction of MART-1-specific T cell immunity in stage IV melanoma patients | |
| B/SE/10/EU-2010-019936-11 | Sweden | 11/05/2010 | Swedish institute for Infectious Disease
ControlInsermKarolinska University Hospital | A phase 1, single centre, dose-escalating, placebo-controlled study of a genetically modified B. pertussis strain given as a single intranasal dose to healthy adult male volunteers | |
| B/ES/10/42 | Spain | 01/03/2010 | Transgene S.A. | A phase II randomized, multicenter, openlabel study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C | |
| B/IT/09/01 | Italy | 04/12/2009 | Merial | Vaccine candidate against Canine Visceral Leishmaniasis. Evaluation of efficacy by natural challenge in an experimental kennel. | |
| B/NL/08/008 | Netherlands | 27/11/2009 | Erasmus MC | A Phase I/II Trial of a Conditionally Replication-Competent Adenovirus (Delta-24-RGD) Administered by Convection Enhanced Delivery in Patients with Recurrent Glioblastoma Multiforme. | |
| B/NL/08/009 | Netherlands | 04/11/2009 | VU Medical Center | A Phase I/II Trial of a Conditionally Replication-Competent Adenovirus (Delta-24-RGD) Administered by Convection Enhanced Delivery in Patients with Recurrent Glioblastoma Multiforme. | |
| B/FI/09/1MA | Finland | 26/10/2009 | MedImmune, LLC | MI-CP208, “A Randomized, Double-Blind Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine in Children”. | |
| B/ES/09/64 | Spain | 21/09/2009 | Institut Català d’Oncologia - IDIBELL | Phase I clinical trial of intravenous administration of a conditionally
replicating adenovirus ICOVIR-5 in patients with locally advanced or metastasic malignant
melanoma. | |
| B/SE/09/EU-2009-011478-13 | Sweden | 15/09/2009 | Swedish institute for Infectious Disease
Control | A phase I trial to assess the safety and feasibility of administering plasmid DNA carrying multiple HIV-1 genes together with dermal electroporation, HIVIS 07 | |
| B/SI/09/01 | Slovenia | 31/08/2009 | University of Ljubljana | Intratumoral application of naked DNA, encoding gene for human interleukin 12, followed by electrically-assisted gene transfer into tumor cells of canine patients | |
| B/GB/09/R43/01 | United Kingdom | 15/07/2009 | MedImmune, LLC | Clinical Study MI-CP178, "A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants"… | |
| B/ES/09/63 | Spain | 14/05/2009 | F. Hoffmann-La Roche, Ltd. | A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5 x 107 pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection. | |
| B/BE/09/BVW1 | Belgium | 11/05/2009 | F. Hoffmann-La Roche, Ltd. | A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5 x 107 pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | |
| B/NL/08/004 | Netherlands | 11/05/2009 | Leiden University Medical Center | A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multicenter Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative Colitis | |
| B/ES/09/62 | Spain | 21/04/2009 | Laboratorios Syva, S.A. León (Spain) | Efficacy and safety assessment of ISPANVAC vaccine in free-ranging wild rabbits.
Location 2. | |
| B/NL/08/005 | Netherlands | 03/04/2009 | Academic Medical Center | A phase II, double blind randomized study to evaluate the immunogenicity of the therapeutic HIV-1 vaccine NYVAC-B versus placebo in chronic HIV-1 infected patients successfully treated with HAART (TheraVac-03) | |
| B/FR/08/09/TG01 | France | 09/01/2009 | MedImmune, LLC | Clinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants”. | |
| B/GB/08/R43/01/S | United Kingdom | 17/12/2008 | MedImmune, LLC | Clinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled,
Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccinelike
Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory
Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-
Old Children and in 2 Month-Old Infants”. | |
| B/BE/08/BVW1 | Belgium | 27/11/2008 | MedImmune, LLC | Clinical Study MI-CP178, A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants. | |
| B/GB/08/R43/01 | United Kingdom | 13/11/2008 | MedImmune, LLC | Clinical Study MI-CP178, A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants | |
| B/NL/08/006 | Netherlands | 05/11/2008 | Vumc | A randomized double-blind placebo-controlled parallel group
study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4mg at 2-weeks intervals on amputation or any death in Critical Limb Ischemia patients with skin lesions | |
| B/FI/08/1MA | Finland | 24/10/2008 | MedImmune, LLC | Clinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants”. | |
| B/ES/08/49 | Spain | 09/10/2008 | MedImmune, LLC | Clinical Study MI-CP178, "A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants". | |
| B/SE/08/EU-2007-006721-27 | Sweden | 26/09/2008 | Ceregene Inc | A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease. | |
| B/ES/08/47 | Spain | 16/09/2008 | Universidad de Navarra | A Phase II, Multicenter, Randomized, Controlled, Open-Label Trial to Compare the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMTalone in Subjects With Idiopathic Parkinson’s Disease. | |
| B/ES/08/48 | Spain | 16/09/2008 | Laboratorios Hipra, S.A. | Assessment of the safety and efficacy of the live vaccine PB-116 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae | |
| B/ES/08/46 | Spain | 09/09/2008 | Sanofi-Aventis Recherche et Développement | A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax® vs.
Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving
chemo-based therapy – EFC10528. | |
| B/NL/08/003 | Netherlands | 09/09/2008 | Stichting Het Nederlands Kanker Instituut | Intradermal vaccination with naked DNA encoding the fusion protein domain1 of tetanus toxin fragment C and MART-1(aa 26-35) for the induction of MART-1-specific T cell immunity in stage IV melanoma patients | |
| B/SE/08/EU-2008-000967-40 | Sweden | 03/07/2008 | ActoGeniX N.V. | A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multicenter Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative Colitis | |
| B/NL/08/001 | Netherlands | 03/07/2008 | Erasmus MC | A randomized double-blind placebo-controlled parallel group study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4mg at 2-weeks intervals on amputation or any death in Critical Limb Ischemia patients with skin lesions | |
| B/ES/07/46 | Spain | 03/07/2008 | Laboratorios Hipra, S.A. | Assessment of the safety and efficacy of the live vaccine PB-35 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae | |
| B/NL/08/002 | Netherlands | 02/07/2008 | Leiden University Medical Center | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg
Intralesional Allovectin-7® [bicistronic plasmid DNA vector VCL-1005 encoding
Human Leukocyte Antigen (HLA)-B7 and β-2 microglobulin, formulated with the
cationic lipid delivery system DMRIE-DOPE] Compared to Dacarbazine (DTIC) or
Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma | |
| B/NL/07/011 | Netherlands | 02/07/2008 | University Medical Center Groningen | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg
Intralesional Allovectin-7® [bicistronic plasmid DNA vector VCL-1005 encoding
Human Leukocyte Antigen (HLA)-B7 and β-2 microglobulin, formulated with the
cationic lipid delivery system DMRIE-DOPE] Compared to Dacarbazine (DTIC) or
Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma | |
| B/NL/07/010 | Netherlands | 10/01/2008 | Erasmus MC, University Medical Center Rotterdam | Study G-0034. A Phase III1 Randomized, Open-Label Study of Docetaxel in combination with CG1940/CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain | |
| B/BE/07/BVW3 | Belgium | 10/01/2008 | GENimmune N.V. | A multi-centre phase I study to evaluate the safety and tolerability of a heterologous prime-boost vaccination with INX102-3697 HBV pDNA/INX-102-00557 HBV MVA in healthy volunteers and HBeAg+ chronic hepatitis patients | |
| B/BE/07/BVW1 | Belgium | 05/12/2007 | ActoGeniX N.V. | Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis (L. lactis). | |
| B/ES/07/44 | Spain | 13/07/2007 | Laboratorios Hipra, S.A. | Assessment of the safety and efficacy
of the live vaccine PB-23 against
Infectious Bovine Rhinotracheitis
under field conditions | |
| B/NL/07/03 | Netherlands | 07/06/2007 | Kiwa Water Research | Field test with sensor based on genetically modified bacteria which can detect toxic compounds in water | |
| B/ES/07/38 | Spain | 29/03/2007 | Laboratorios Syva, S.A. León (Spain) | Efficacy and safety assessment of ISPANVAC vaccine in free-ranging wild rabbits. | |
| B/NL/06/003 | Netherlands | 04/12/2006 | University Hospital Maastricht | Study G-0029
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naive (G-0029) | |
| B/NL/06/010 | Netherlands | 04/12/2006 | Raboud University Medical Center | Study G-0029 A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naive (G-0029) | |
| B/NL/06/011 | Netherlands | 04/12/2006 | AMC Amsterdam | Study G-0034
A Phase III Randomized, Open-Label Study of Docetaxel in combination with CG1940/CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain | |
| B/NL/06/009 | Netherlands | 27/10/2006 | Academic Medical Center | An open-label phase I study to evaluate the safety of the HIV-1 vaccine MVA-B in chronic HIV-1 infected patients successfully treated with HAART | |
| B/NL/06/001 | Netherlands | 08/09/2006 | Study G-0029
University Medical Center GroningenStudy G-0034
VU Medical Center | A Phase III1 Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naive (G-0029)
---
A Phase III1 Randomized, Open-Label Study of Docetaxel in combination with CG1940/CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain (G 0034) | |
| B/ES/06/42 | Spain | 12/07/2006 | Oxford BioMedica UK Ltd. | An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma. (TV3/001/06) | |
| B/SE/06/EU-2006-000985-34 | Sweden | 15/05/2006 | Uppsala University, Division of Clinical Immunology, Uppsala. | A Phase I-IIa Study of Dose-escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma | |
| B/NL/05/006 | Netherlands | 24/04/2006 | Erasmus MC, University Medical Center Rotterdam | Adjuvant IL-12 immuno-gene therapy prior to radical prostatectomy in patients with prostate cancer | |
| B/ES/06/40 | Spain | 29/03/2006 | Laboratorios Syva, S.A. León (Spain) | Safety in pregnant does and duration of immunity assessment of a vaccine based on the virus strain 6918VP60. | |
| B/FR/06/03/02 | France | 16/03/2006 | Merial Laboratoires | Development of a vaccine against feline rabies. Experiment outside containment (clinical trial) for the study of the safety and the efficacy of a subcutaneous administration of a recombinant canarypoxvirus expressing the surface glycoprotein G gene from Rabies virus (vCP65). | |
| B/GB/06/R40/01 | United Kingdom | 16/03/2006 | Emergent Europe Ltd | A double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of a candidate oral immunotherapy (M04NM11, formerly called hepatitis B Candidate 1) in patients who have chronic Hepatitis B infection. | |
| B/NL/05/02 | Netherlands | 09/09/2005 | Rijksinstituut voor Volksgezondheid en Milieu | Exploring the health effects due to air
pollution by exposure of transgenic mice and rats at location | |
| B/ES/05/26 | Spain | 19/07/2005 | Laboratorios Syva, S.A. León (Spain) | Valoration of effects in rapacious birds and european lynx associated with ingestion of
rabbits innoculated with a vaccine based on the strain 6918VP60. | |
| B/SE/05/151:2005/30190 | Sweden | 10/06/2005 | Swedish institute for Infectious Disease
Control | Assessment of the safety and immunogenicity of administering MVA, carrying HIV-1 genes
env, gag, and pol in subjects who have previously received plasmid DNA with analogous HIV-
1 genes in HIVIS 01. | |
| B/NL/05/001 | Netherlands | 26/05/2005 | Academic Medical Center | Administration of AMT-010, an adenoassociated viral vector (AAV) encoding lipoprotein lipase variant S447X (LPLS447X) to LPL deficient patients | |
| B/SE/05/KEMI-723-573 | Sweden | 25/04/2005 | Swedish University of Agricultural Sciences - SLU | Risk assessment of non-resident microorganisms used for biocontrol of fungal pathogens. |  |
| B/ES/05/01 | Spain | 09/03/2005 | Consejo Superior de Investigaciones Científicas | Field trial of a vaccinie against canine Leishmaniasis | |
| B/NL/04/001 | Netherlands | 29/09/2004 | Pfizer Animal Health | Evaluation of the safety of a Feline Herpes virus, bivalent gene deleted live vaccine, administered as intranasal vaccination to cats | |
| B/BE/04/BV1 | Belgium | 15/09/2004 | Pfizer Animal Health | Evaluation of the safety of a Feline Herpes
virus, bivalent gene deleted live vaccine, administered as intranasal vaccination to cats | |
| B/NL/03/08 | Netherlands | 04/05/2004 | VU Medical Center | A phase 1 dose escalation trial of MDX- 010 in combination with CG1940 and CG8711 in patients with metastatic HRPC | |
| B/NL/03/02 | Netherlands | 19/03/2004 | Erasmus MC, University Medical Center Rotterdam | Artificial colonization of clumping factor B deficient Staphylococcus aureus in the nose | |
| B/GB/04/R39/1 | United Kingdom | 19/03/2004 | Natural Environment Research Council (UK) | Strategies for risk assessment, evaluating the environmental impact of fungal diseases suppressing GM bacteria on non-target species | |
| B/BE/03/B3 | Belgium | 01/03/2004 | Transgene S.A. | Study TG1024.01: "Phase I multicentre study of TG1024 (Adenovirus interleukin 2) in patients with metastatic melanoma or other advanced solid tumor cancers" | |
| B/NL/03/05 | Netherlands | 19/12/2003 | International AIDS Vaccine Initiative, New York, USA | A double-blind, randomized, placebo controlled dose-escalating phase 1 study to evaluate the safety and immunogenicity of a MVA HIV-1 vaccine administered by three different routes and at three different dosage levels in HIV-uninfected healthy volunteers at lower risk of infection. | |
| B/NL/03/01 | Netherlands | 12/08/2003 | Academisch Ziekenhuis Leiden | Gene therapy in aseptic prosthetic replacement loosening. A phase 1 study | |
| B/ES/03/35 | Spain | 23/06/2003 | Schering Espana SA | Development of an Angiogenic Gene Therapy Product for Coronary Artery Disease. | |
| B/GB/03/35/03 | United Kingdom | 06/06/2003 | Acambis Research Ltd | Live attenuated vaccine for prevention of travellers’ diarrhoea | |
| B/GB/03/R35/02 | United Kingdom | 10/02/2003 | Acambis Research Ltd | Phase I clinical trial of a live attenuated Salmonella typhi vaccine for the prevention of typhoid fever | |
| B/GB/02/37/02 | United Kingdom | 10/02/2003 | Microscience Ltd. | An open-label study to determine the safety and immunogenicity of two dose levels (10E8 or 10E9 CFU) of a candidate oral immunotherapy (Hep B Candidate 1) against hepatitis B, given on two occasions, 56 days apart to healthy subjects | |
